Cowen and Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cowen and Company’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-29,900	Closed	-$8K	–	762
2022 Q1	$8K	Buy	+29,900	New	+$2.76M	﹤0.01%	520
2021 Q2	–	Sell	-8,500	Closed	-$25K	–	717
2021 Q1	$25K	Sell	8,500 -41,100	-83%	-$6.15M	﹤0.01%	443
2020 Q4	$236K	Buy	49,600 +27,600	+125%	+$3.54M	0.02%	168
2020 Q3	$26K	Buy	+22,000	New	+$2.47M	﹤0.01%	339
2020 Q2	–	Sell	-7,200	Closed	-$35K	–	485
2020 Q1	$35K	Sell	7,200 -102,800	-93%	-$9.1M	0.01%	302
2019 Q4	$250K	Buy	110,000 +106,100	+2,721%	+$9.18M	0.02%	184
2019 Q3	$5K	Buy	+3,900	New	+$324K	﹤0.01%	424

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Cowen and Company's XBI Position: Q4 2021 in Review

Cowen and Company sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2021, closing a stake of 400,000 shares — an estimated $50.3M sold.

Cowen and Company first reported a position in XBI in Q4 2019 and held it in 7 quarters. The position peaked at $60.8M in Q2 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q4 2021.

Cowen and Company reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2021 after selling out during the quarter.
Cowen and Company sold 400,000 State Street SPDR S&P Biotech ETF shares in Q4 2021, an estimated $50.3M.
Cowen and Company first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and held it in 7 quarters.
Cowen and Company's State Street SPDR S&P Biotech ETF position peaked at $60.8M in Q2 2021.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.